SCHEMBL16631215

SCHEMBL16631215

Cc1nc2cn([C@@H]3O[C@H](CO)C(O)[C@@H]3O)c(=S)nc2[nH]c1=O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PYGM P11217 3/20 0.47
LMNA P02545 2/20 0.45
MTOR P42345 2/20 0.45
GMNN O75496 1/20 0.45
ALDH1A1 P00352 1/20 0.45
TP53 P04637 1/20 0.45
NFKB1 P19838 1/20 0.45
DNMT1 P26358 1/20 0.45
THPO P40225 1/20 0.45
HTT P42858 1/20 0.45
RAB9A P51151 1/20 0.45
BLM P54132 1/20 0.45
HBB P68871 1/20 0.45
PMP22 Q01453 1/20 0.45
HPGD P15428 1/20 0.44
SLC28A1 O00337 1/20 0.44
SLC28A2 O43868 1/20 0.44
SLC29A1 Q99808 1/20 0.44
SLC28A3 Q9HAS3 1/20 0.44
TK2 O00142 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18080236 1.00 PYGM (0.47) PYGMLMNAMTORGMNNALDH1A1
SCHEMBL18080172 0.89 LMNA (0.52) PYGMLMNAMTORGMNNALDH1A1
SCHEMBL16631207 0.89 LMNA (0.52) PYGMLMNAMTORGMNNALDH1A1
SCHEMBL16631236 0.87 PYGM (0.47) PYGMLMNAMTORGMNNALDH1A1
SCHEMBL18080196 0.87 PYGM (0.47) PYGMLMNAMTORGMNNALDH1A1
SCHEMBL18080317 0.87 CDK1 (0.43) PYGMLMNAMTORGMNNALDH1A1
SCHEMBL16631887 0.86 LMNA (0.46) LMNAHBBPMP22MAPT
SCHEMBL16631356 0.83 PYGM (0.47) PYGMLMNAMTORGMNNALDH1A1
SCHEMBL16631313 0.83 CDK1 (0.47) PYGMLMNAMTORGMNNALDH1A1
SCHEMBL16631330 0.82 PYGM (0.42) PYGMLMNAMTORGMNNALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160264614-A1 POLYNUCLEOTIDE MOLECULES AND USES THEREOF MODERNA THERAPEUTICS, INC. (US) 2016-09-15 US disclosed
WO-2015051173-A2 POLYNUCLEOTIDE MOLECULES AND USES THEREOF MODERNA THERAPEUTICS, INC (US) 2015-04-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160264614-A1 POLYNUCLEOTIDE MOLECULES AND USES THEREOF POLRMT, POLN, NSUN3 PYGM 303/4885LMNA 776/4885MTOR 4754/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.